Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

.

WellCare Health Plans

(

WCG

) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.5%. By the end of trading, WellCare Health Plans fell 79 cents (-1.3%) to $59.87 on light volume. Throughout the day, 435,891 shares of WellCare Health Plans exchanged hands as compared to its average daily volume of 1.1 million shares. The stock ranged in price between $59.81-$60.86 after having opened the day at $60.65 as compared to the previous trading day's close of $60.66. Other companies within the Health Care sector that declined today were:

Questcor Pharmaceuticals

(

QCOR

), down 47.8%,

USMD Holdings

(

USMD

), down 26.4%,

Somaxon Pharmaceuticals

(

SOMX

), down 11.2%, and

Idenix Pharmaceuticals

(

IDIX

), down 9.4%.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

WellCare Health Plans, Inc. provides managed care services for government-sponsored health care programs in the United States. WellCare Health Plans has a market cap of $2.61 billion and is part of the

health services

industry. The company has a P/E ratio of 9.8, equal to the average health services industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 15.6% year to date as of the close of trading on Tuesday. Currently there are five analysts that rate WellCare Health Plans a buy, no analysts rate it a sell, and six rate it a hold.

TheStreet Ratings rates WellCare Health Plans as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity and attractive valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front,

Graymark Healthcare

(

GRMH

), up 33.9%,

Cyclacel Pharmaceuticals

(

CYCC

), up 27.2%,

MEI Pharma

(

MEIP

), up 23.7%, and

Galectin Therapeutics

(

GALT

), up 18.5%, were all gainers within the health care sector with

AstraZeneca

(

AZN

) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!

Free download now

.

null